| Overview |
| bs-70354r-100ul |
| Atrogin-1 Antibody |
| WB, IHC |
| This antibody detects a 41 kDa* protein corresponding to the apparent molecular mass of Atrogin on SDS-PAGE immunoblots of mouse muscle tissue lysates. Similar results were seen in C2C12 cell lysate and the band observed in western blot is specifically blocked by Atrogin-1 peptide (AX2045). This sequence is highly homologous to human and rat Atrogin (F-box only protein 32). |
| Human, Mouse, Rat |
| Specifications |
| Unconjugated |
| Rabbit |
| A synthetic peptide (coupled to carrier protein) corresponding to amino acids from the N-terminal region of mouse Atrogin. |
| Polyclonal |
| IgG |
| Antigen Affinity purification |
| PBS + 1 mg/ml BSA, 0.05% NaN3 and 50% glycerol |
| Storage at -20°C is recommended, as aliquots may be taken without freeze/thawing due to presence of 50% glycerol. Stable for at least 1 year at -20°C. |
| Target |
| Q9CPU7 |
| MAFbx, FBX32, Atrogin |
| Atrogin-1/Muscle Atrophy F-box (MAFbx) is an E3 ubiquitin ligase that mediates proteolysis events that occur during muscle atrophy. This ATP-dependent ubiquitin-mediated proteolysis occurs in response to a variety of catabolic states in muscle. Atrogin is expressed in heart and skeletal muscle, and is upregulated during muscle atrophy. In addition, Atrogin expression increases in C2C12 myotubes after stimulation with cytokines. Atrogin is thought to recognize and bind to some phosphorylated proteins and promote their ubiquitination and degradation during skeletal muscle atrophy. Atrogin interacts with MyoD by ubiquitination via a sequence found in transcriptional coactivators and therefore may play an important role in the course of muscle differentiation by determining the abundance of MyoD. Mice deficient in Atrogin are resistant to muscle atrophy. |
| Application Dilution |
| WB |
1:300-5000 |
| IHC |
|
Powered by Bioz